These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 32954807)

  • 61. Cell-of-origin effect of polatuzumab vedotin in diffuse large B-cell lymphoma: no ordinary subgroup analysis.
    Russler-Germain DA; Cliff ERS; Bartlett NL
    Blood; 2023 Dec; 142(25):2216-2219. PubMed ID: 37797275
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed/refractory multiple myeloma.
    Lee HC; Raje NS; Landgren O; Upreti VV; Wang J; Avilion AA; Hu X; Rasmussen E; Ngarmchamnanrith G; Fujii H; Spencer A
    Leukemia; 2021 Jan; 35(1):255-258. PubMed ID: 32317775
    [No Abstract]   [Full Text] [Related]  

  • 63. Polatuzumab Vedotin: Current Role and Future Applications in the Treatment of Patients with Diffuse Large B-Cell Lymphoma.
    Assi R; Masri N; Dalle IA; El-Cheikh J; Ghanem H; Bazarbachi A
    Clin Hematol Int; 2021 Mar; 3(1):21-26. PubMed ID: 34595463
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Diffuse large B-cell lymphoma: new targets and novel therapies.
    Cheson BD; Nowakowski G; Salles G
    Blood Cancer J; 2021 Apr; 11(4):68. PubMed ID: 33820908
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Treatment of refractory diffuse large B-cell lymphoma involving the central nervous system with polatuzumab vedotin-based regimen: a case report and literature review].
    Bai JF; Feng R; Wang T; Li X; Qian L; Li JT; Zhang CL; Liu H
    Zhonghua Xue Ye Xue Za Zhi; 2024 Sep; 45(9):864-866. PubMed ID: 39414613
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Novel agents in relapsed/refractory diffuse large B-cell lymphoma.
    Varma G; Goldstein J; Advani RH
    Hematol Oncol; 2023 Jun; 41 Suppl 1():92-106. PubMed ID: 37294966
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Successful polatuzumab vedotin and rituximab therapy for post-CAR-T relapse of diffuse large B-cell lymphoma].
    Kushida T; Hirosawa M; Goto M; Seike Y; Kitamura N; Nakanishi T; Tanaka A; Higashi T; Morimoto H; Tsukada J
    Rinsho Ketsueki; 2024; 65(3):180-182. PubMed ID: 38569863
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma.
    Corcoran SR; Phelan JD; Choi J; Shevchenko G; Fenner RE; Yu X; Scheich S; Hsiao T; Morris VM; Papachristou EK; Kishore K; D'Santos CS; Ji Y; Pittaluga S; Wright GW; Urlaub H; Pan KT; Oellerich T; Muppidi J; Hodson DJ; Staudt LM
    Cancer Discov; 2024 Sep; 14(9):1653-1674. PubMed ID: 38683128
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a multicenter retrospective analysis.
    Hong JY; Yoon DH; Suh C; Kim WS; Kim SJ; Jo JC; Kim JS; Lee WS; Oh SY; Park Y; Kim SY; Lee MH; Lee HS; Do YR
    Ann Hematol; 2018 Aug; 97(8):1437-1443. PubMed ID: 29619501
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Polatuzumab vedotin plus bendamustine and rituximab (Pola-BR) was effective for neurolymphomatosis in a patient with refractory diffuse large B-cell lymphoma.
    Shinmura K; Okubo S; Kadota S; Nakayama H; Sakurai A; Kurosawa S; Ito C; Aisa Y; Nakazato T
    Ann Hematol; 2023 Jan; 102(1):223-225. PubMed ID: 36394579
    [No Abstract]   [Full Text] [Related]  

  • 71. A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemia.
    Narayan R; Blonquist TM; Emadi A; Hasserjian RP; Burke M; Lescinskas C; Neuberg DS; Brunner AM; Hobbs G; Hock H; McAfee SL; Chen YB; Attar E; Graubert TA; Bertoli C; Moran JA; Bergeron MK; Foster JE; Ramos AY; Som TT; Vartanian MK; Story JL; McGregor K; Macrae M; Behnan T; Wey MC; Rae J; Preffer FI; Lesho P; Duong VH; Mann ML; Ballen KK; Connolly C; Amrein PC; Fathi AT
    Cancer; 2020 Mar; 126(6):1264-1273. PubMed ID: 31860140
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Use of R-mini-CHP in combination with polatuzumab vedotin (pola-R-mini-CHP) as the primary treatment in ≥80-year-old cases with diffuse large B-cell lymphoma.
    Sekiguchi Y; Tsutsumi H; Gomyo A; Kudo M; Iizaki Y; Maseki N; Kawamura M; Kobayashi K; Nishimura Y; Kanda H; Nitta H; Noguchi M; Kobayashi H
    J Clin Exp Hematop; 2023; 63(4):262-265. PubMed ID: 38148017
    [No Abstract]   [Full Text] [Related]  

  • 73. Treatment of classical Hodgkin lymphoma in the era of brentuximab vedotin and immune checkpoint inhibitors.
    Carella AM; Corradini P; Mussetti A; Ricardi U; Vitolo U; Viviani S
    Ann Hematol; 2018 Aug; 97(8):1301-1315. PubMed ID: 29802458
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression.
    Jacobsen ED; Sharman JP; Oki Y; Advani RH; Winter JN; Bello CM; Spitzer G; Palanca-Wessels MC; Kennedy DA; Levine P; Yang J; Bartlett NL
    Blood; 2015 Feb; 125(9):1394-402. PubMed ID: 25573987
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Time-to-Event Analysis of Polatuzumab Vedotin-Induced Peripheral Neuropathy to Assist in the Comparison of Clinical Dosing Regimens.
    Lu D; Gillespie WR; Girish S; Agarwal P; Li C; Hirata J; Chu YW; Kagedal M; Leon L; Maiya V; Jin JY
    CPT Pharmacometrics Syst Pharmacol; 2017 Jun; 6(6):401-408. PubMed ID: 28544534
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Pseudoprogression of triple-hit diffuse large B-cell lymphoma following polatuzumab vedotin-based salvage therapy.
    Wang X; McIntosh L; Selove WJ; Zivny J; Cerny J
    Leuk Lymphoma; 2021 Aug; 62(8):2022-2025. PubMed ID: 33719894
    [No Abstract]   [Full Text] [Related]  

  • 77. Targeting MCL-1 and BCL-2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R non-Hodgkin lymphoma: Results from preclinical models and a Phase Ib study.
    Lasater EA; Amin DN; Bannerji R; Mali RS; Barrett K; Rys RN; Oeh J; Lin E; Sterne-Weiler T; Ingalla ER; Go M; Yu SF; Krem MM; Arthur C; Hahn U; Johnston A; Karur V; Khan N; Marlton P; Phillips T; Gritti G; Seymour JF; Tani M; Yuen S; Martin S; Chang MT; Rose CM; Pham VC; Polson AG; Chang Y; Wever C; Johnson NA; Jiang Y; Hirata J; Sampath D; Musick L; Flowers CR; Wertz IE
    Am J Hematol; 2023 Mar; 98(3):449-463. PubMed ID: 36594167
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Antibody-Drug Conjugate for Treating Leukemia and Lymphoma-The Present Status, Problems, and Future Development].
    Ida N; Yamauchi T
    Gan To Kagaku Ryoho; 2024 Jul; 51(7):686-690. PubMed ID: 39191681
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma.
    Stewart AK; Krishnan AY; Singhal S; Boccia RV; Patel MR; Niesvizky R; Chanan-Khan AA; Ailawadhi S; Brumm J; Mundt KE; Hong K; McBride J; Shon-Nguyen Q; Xiao Y; Ramakrishnan V; Polson AG; Samineni D; Leipold D; Humke EW; McClellan JS; Berdeja JG
    Blood Cancer J; 2019 Feb; 9(2):17. PubMed ID: 30718503
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study.
    Salles G; Duell J; González Barca E; Tournilhac O; Jurczak W; Liberati AM; Nagy Z; Obr A; Gaidano G; André M; Kalakonda N; Dreyling M; Weirather J; Dirnberger-Hertweck M; Ambarkhane S; Fingerle-Rowson G; Maddocks K
    Lancet Oncol; 2020 Jul; 21(7):978-988. PubMed ID: 32511983
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.